October Products

By Mallory Griffin

KACTUS has developed the following new products to facilitate the latest innovations in drug development. Select a product category to jump to a specific section. Alternatively, click here to view all new products

Jump to Specific Category:
VLP Super Antigens
Drug Discovery Targets
SARS-COV-2 & Monkeypox
KRAS Proteins

KACTUS now offers glypican-3 (GPC3) protein and the G protein-coupled receptor GPRC5D as VLPs. GPC3 is a potential antibody therapeutic target for liver and other cancers. GPRC5D was thought to be expressed only in hair follicles but recently has shown potential as a CAR-T therapy target for myeloma. View our entire collection of VLPs here.



Cadherins play an important role in tissue homeostasis, as they are responsible for cell-cell adhesion during embryogenesis, tissue morphogenesis, differentiation and carcinogenesis. KACTUS has added new cadherin proteins including CDH-1, CDH-6, CDH-17, and CDH-19. These play a role in epithelial cell junctions, prostate cancer tumor growth, and Schwann cell development. View our entire collection of cadherins here. 

Human CDH6

Cynomolgus E-Cadherin

Cynomolgus CDH6

Human CDH6

Rhesus macaque CDH17
Mouse CDH6


KACTUS has developed new proteins for drug discovery including MICA alpha 3 protein which plays a role in tumor evasion and Notch 3 protein which forms a transcriptional activator complex upon ligand binding. Additionally, KACTUS has developed a recombinant form of the adipocyte-derived hormone adiponectin and the hepatokine angiopoietin-like 3 protein, both of which play a role in lipid and glucose metabolism. View the full line new drug discovery targets below. 

Cynomolgus ANGPTL3

Mouse ENPP-1

Cynomolgus Adiponectin

Human MICA alpha 3

Biotinylated Human

Notch 3 Protein

 Cynomolgus IFN

alpha/beta R1 

Cynomolgus TRAIL




SARS-COV-2 & Monkeypox

KACTUS continues to contribute to COVID-19 therapeutics with the release of two variations of SARS-COV-2 3C-like proteases. Additionally, with the new Monkeypox outbreak beginning in May 2022, KACTUS has developed two monkeypox virus proteins to assist drug discovery and development.

Monkeypox virus A35R

SARS-CoV-2 3CLpro /

3C-like Protease

Monkeypox virus M1R

SARS-CoV-2 3CLpro /

3C-like Protease (L50F, E166V)


Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is part of the RAS/MAPK pathway and plays a role in cell division, differentiation, and apoptosis. It is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. 

Human KRAS G12A


Biotinylated Human KRAS G12S


Biotinylated Human KRAS G12A


Human KRAS G12S


Human KRAS G12C




Interleukin-8 (IL-8) is a promising target for central nervous system disorders like glioma. IL-27 modulates inflammation with innate and adaptive immune cells. These are only a selection of IL products offered by KACTUS. View all of our interleukin proteins here.  

Human IL-27 Protein

Cynomolgus IL-8/CXCL8 Protein

Cynomolgus IL-18BP Protein



Other Products

Human MASP3 Protein

Mouse XPNPEP2 Protein

Human MBL2 / Mannan

Binding Lectin Protein

Human XPNPEP2 Protein

Human MRC2 Protein

Human Tulp1 Protein

Human OSMR&GP130 Protein

Human Tubby Protein

Cynomolgus AGER Protein

Canine CEACAM-1 /

CD66a Protein